Key statistics dashboard for IN8bio, Inc. (INAB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies.
Stock Data
| Price | $1.01 |
| Market Cap | $10M |
| Enterprise Value | -$6.1M |
| Beta | 0.04 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.56 |
| Price / Book | 1.11 |
| P/S | 0.00 |
| EV/EBITDA | 0.36 |
| EV/Sales | 0.00 |
| EV/FCF | 0.42 |
| P/FCF | -0.69 |
| Earnings Yield | -94.94% |
| FCF Yield | -150.71% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -91.18% |
| Return on Assets | -85.85% |
| Return on Invested Capital | -91.74% |
| Return on Capital Employed | -96.68% |
Financial Health
| Current Ratio | 8.21 |
| Quick Ratio | 8.21 |
| Cash Ratio | 7.97 |
| Debt / Equity | 0.12 |
| Debt / Assets | 10.01% |
| Net Debt / EBITDA | 0.94 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.94 |
| Cash per share | 0.92 |
| FCF per share | -0.75 |
| Tangible Book Value per share | 0.94 |
| Dividend per share | 0.00 |
Related companies: ACXP · APRE · APVO · BCDA · GLTO · HCWB · KPRX
Explore sector: Healthcare · Biotechnology
More sections of INAB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks